Parameter estimation and treatment optimization in a stochastic model
  for immunotherapy of cancer by Diabate, Modibo et al.
PARAMETER ESTIMATION AND TREATMENT OPTIMIZATION IN
A STOCHASTIC MODEL FOR IMMUNOTHERAPY OF CANCER
MODIBO DIABATE, LOREN COQUILLE, AND ADELINE SAMSON
Abstract. Adoptive Cell Transfer therapy of cancer is currently in full development
and mathematical modeling is playing a critical role in this area. We study a stochastic
model developed by Baar et al., 2015 for modeling immunotherapy against melanoma skin
cancer.
In the first part, we estimate the parameters of the deterministic limit of the model
based on biological data of tumor growth in mice. A Nonlinear Mixed Effects Model is
estimated by the Stochastic Approximation Expectation Maximization algorithm. With
the estimated parameters, we head back to the stochastic model and calculate the prob-
ability that the T cells all get exhausted during the treatment. We show that for some
relevant parameter values, an early relapse is due to stochastic fluctuations (complete T
cells exhaustion) with a non negligible probability.
In the second part, focusing on the relapse related to the T cell exhaustion, we propose
to optimize the treatment plan (treatment doses and restimulation times) by minimizing
the T cell exhaustion probability in the parameter estimation ranges.
1. Introduction
Cancer is a group of more than 100 different diseases causing a large number of deaths
a year worldwide [14]. It begins when cells start to grow uncontrollably due to genetic
changes which impair their normal evolution. It can develop almost anywhere in the body.
Cancer is a complex disease, difficult to study biologically (expensive and time consuming
to experiment with animals and humans). In this context, mathematical modeling can
be an excellent tool for emitting or confirming biological assumptions with less expensive
experiments.
When it is diagnosed quickly, cancer can be treated by chemotherapy, surgery, radio-
therapy or by immunotherapy [2, 16, 22, 30]. Immunotherapy is a recent treatment that
activates the immune system to kill cancer cells. In this paper we are interested by the
Adoptive Cell Transfer (ACT) therapy to treat melanoma in mice with cytotoxic T cells,
as experimented by Landsberg et al., 2012. This immunotherapeutic approach involves
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Figure 1. Main cell interactions in ACT Therapy: The killing of a differentiated melanoma
cell by a T cell produces more T cells and cytokines TNFα (first line); the switch between
differentiated and dedifferentiated melanoma cells is reversible (second line); a T cell cannot kill
a dedifferentiated melanoma cell (third line) [4, 21].
the stimulation of T cells which recognize one specific type of melanoma tumor cells (dif-
ferentiated melanoma cells) through special markers on their surface. The stimulated T
cells are then able to kill these differentiated melanoma cells. The authors of [21] showed
that during the inflammation induced by the therapy, pro-inflammatory cytokines called
TNFα (Tumor Necrosis Factor) which are released in the body enhance a cell-type switch:
the markers on the differentiated cancer cells disappear. They become dedifferentiated,
and cannot get killed by T cells anymore. The resulting tumor tissue consists of both
differentiated and dedifferentiated melanoma cells. Note that the switch is reversible (i.e,
the melanoma cells can recover their initial type) and it does not require cell division or
mutation. Figure 1 illustrates the described interactions between cells during the treat-
ment: the production of more T cells (plus the production of cytokines TNFα) when a
T cell kills a differentiated melanoma cell; the cell-type switch between differentiated and
dedifferentiated melanoma cells; and the fact that a T cell cannot kill a dedifferentiated
melanoma cell.
In immunotherapy (as in other treatments against cancer) the relapse is one of the
main problems to manage. The authors of [4, 21] describe two kinds of relapse in the ACT
therapy. First, T cells only recognize the differentiated cancer cells through special markers
and not the dedifferentiated cancer cells that do not possess these markers on their surface.
Thus, T cells are not capable of killing these dedifferentiated cells, which growth implies a
relapse as shown on Figure 2. Second, T cells can become exhausted (their quantity falls
down below a certain threshold) and they no longer kill differentiated cancer cells thus
causing a relapse. This problem was addressed in [21] by T cells restimulation, which only
lead to a delay in the occurrence of the relapse.
In these recent years, a lot of potentials have been seen in immunotherapy treatments,
including the possibility of higher effectiveness [31] with lower side effects. It should be
noted that, while immunotherapy techniques have shown very few and less serious side
effects, long-term effects have not yet been studied in clinical trials. These promising
new treatments are thus still to be understood. An alternative to long clinical trials
which are costly is to study long term effects (treatment failure and relapse) through the
development of mathematical models. Numerous mathematical models have been proposed
for the cancer study: deterministic models mainly based on partial differential equations
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Figure 2. Relapse with dedifferentiated melanoma cells (in red) not killed by T cells [21].
The ACT therapy induces an inflammation and the melanoma cells react to this environmental
change by switching their type (special markers on the differentiated melanoma cell surface
disappear). The T cells are not capable of killing switched differentiated melanoma cells, and a
relapse is observed: the tumor grows again. The switch thus allows tumors to be resistant to the
therapy.
or ordinary differential equations [5, 25, 33, 34], stochastic models like individual-based
models or diffusion models [4, 8, 26] and often a combination of both [3, 28].
The purpose of the present paper is to study the relapse and failure of skin cancer
immunotherapy in mice using mathematical models and real biological data. First, we
estimate the parameters of the mathematical model developed by Baal et al. [4] which is
adapted to the problem. Then, with the estimated parameters, we study the treatment
relapse and failure focusing on T cell exhaustion and propose to optimize the treatment
plan.
The stochastic individual-based model recently proposed by [4] aims to describe the ACT
therapy presented in the article [21]. Its main features are: modeling the reproduction
and the death of cancer cells and active T cells with birth and death processes [19] (the
stimulation of T cells is modeled as birth of active T cells and their exhaustion as death of
active T cells); modeling the switch between the two types of melanoma cancer cells; taking
into account the interactions between cancer cells and T cells in a predator-prey framework
[6, 10]. The different events (reproduction, death and switch events) occur at exponential
random times in the model calibrated by rate parameters. The large population limit
(large number of cells) of the stochastic model is a deterministic differential system [4].
The authors of [4] have provided a set of biologically relevant parameters for which the
stochastic system exhibits exhaustion of the T cells with high probability. However, these
parameters have been calibrated numerically [4] but not estimated from real data. Our
first objective is thus to estimate these parameters from the biological data given in [21].
The direct estimation of parameters in the stochastic model is problematic due to its like-
lihood function defined as a multiple integral over a high dimension event space. To the
best of our knowledge, there exists no statistical method to estimate the parameters of
such models. As an approximation, we consider the likelihood of the deterministic differen-
tial system. We therefore estimate the parameters of the model through its deterministic
limit using experimental data of tumor growth in mice provided by [21]. The database
is composed of tumor size measurements along time in three groups of mice: a control
group showing the tumor growth in absence of treatment, a group treated with ACT ther-
apy and a group treated with ACT therapy and restimulation, i.e. reinjection of T cells.
PARAMETER ESTIMATION IN A STOCHASTIC MODEL FOR IMMUNOTHERAPY 4
This last group allows to study the effect of the restimulation on the relapse. We analyze
these longitudinal data simultaneously with a Nonlinear Mixed Effects Model (NLMEM)
[27] that takes into account the variability between the mice (population and individual
parameters are estimated). Indeed, longitudinal data are very common in cancer studies.
Mixed effects models [27] are well adapted to such data and are often involved in param-
eter estimation in cancer models [7, 12, 17]. The Stochastic Approximation Expectation
Maximization (SAEM) algorithm [11] is used to estimate the parameters of the NLMEM.
Once the parameters have been estimated, T cell exhaustion is studied by heading back
to the stochastic model. Indeed, complete exhaustion is a purely stochastic phenomenon
which is not modeled by the deterministic system. As T cell exhaustion can be a rare event,
we estimate it using a splitting Monte Carlo method adapted to rare event probability
estimation [18, 24]. We observe that, in the range of parameters estimated from real data,
the exhaustion probability can be non negligible, which confirms a conjecture in [4].
As this kind of relapse can be delayed by restimulation of T cells, our second objective
is to optimize the ACT protocol in this sense. We propose a treatment optimization
plan based on the computation of optimal treatment doses and restimulation times by
minimizing the T cell exhaustion probability at different stages of the disease evolution.
The paper is organized as follows. In section 2 we present the experimental data used
for parameter estimation. In section 3, the stochastic model and its deterministic limit
are described. In section 4, we first present the statistical tools involved in the parameter
estimation of the deterministic system, as well as the estimated parameter values. Second,
we describe the T cell exhaustion probability estimation procedure and estimate the ex-
haustion probability as a function of the T cells death rate. In section 5, we perform the
ACT treatment optimization and present the related results.
2. Experimental data on Adoptive Cell Transfer therapy
We first describe the experimental setup of [21], from which we use the data. Initially,
a small quantity M0 of melanoma cells (around 10
4) is placed inside each mouse of the
experiment. Thus, the initial size of the tumor is very small. Mice are then split into 3
groups: untreated mice playing the role of a control group (denoted CTRL) and treated
mice composed of two subgroups: mice treated once with ACT therapy (denoted ACT)
and mice treated twice with ACT therapy (denoted ACT+Re). After 70 days (at time
ta = 70), mice of ACT and ACT+Re groups receive a dose d70 of a T cell stimulant
activating 2000 T cells and conferring them the ability to kill differentiated melanoma
cells. Mice in ACT+Re group receive an additional dose dRe of the T-cell stimulant at
restimulation time tRe = 160 activating again 2000 T cells.
During the experiment, the tumor development is measured by palpation when the tumor
is small and digital photography when the tumor is larger. The tumor size is measured
weekly using a vernier caliper and recorded as mean diameter [21]. Longitudinal data for
19 mice are composed of 5 mice of CTRL group (with an average number of 10 observations
per mouse); 7 mice of ACT group (with an average number of 26 observations); and 7 mice
of ACT+Re group (with an average number of 33 observations).
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Figure 3. Tumor diameter (mm) along time (days) in the groups CTRL (dashed line in
blue), ACT (solid line in red), ACT+Re (dotted line in green). The three types of censorship
are indicated by the horizontal lines at diameter = 1.99 mm, 3 mm and 10 mm. The treatment
at the 70th day and the re-treatement at the 160th day (for ACT+Re mice) are indicated by the
vertical dotted lines.
The measure of tumor size, if it is smaller than 2 mm, is very inaccurate due to the
difficulties of palpation. Thus, these values are left censored. For tumor size between 2
mm and 3 mm, the inaccuracy is still important on the measures, about 1 mm. These
values are interval censored in [2, 3]. Mice with tumor size exceeding 10 mm or showing
signs of illness are killed. Thus measurements exceeding 10 mm are considered as right
censored. The other tumor sizes between 3 mm and 10 mm are considered as measured
correctly with a measurement accuracy around 0.5 mm.
Figure 3 represents the evolution of the tumor diameter along time for all the mice. The
three censorships are illustrated by aligned horizontal points. Excluding the observations
at t0 = 0, mice in CTRL group are not concerned by left-censorship. Observe that the
three groups of mice are distinguished by the rapidity in the evolution of their tumor
size: tumor size of CTRL group (in blue) reaches quickly 10 mm around the 100th day,
tumor size of ACT group (in red) reaches 10 mm between the 240 and 300 days and finally
tumor size of ACT+Re group (in green) reaches 10 mm beyond the 300th day. Treatment
and retreatment times are indicated by (black) vertical dotted lines. We distinguish two
phases in the ACT therapy (for treated mice): the growth phase (before ta = 70) and the
treatment phase (after ta = 70). Note that the mice in CTRL group have only the tumor
growth phase.
3. Modeling tumor growth under treatment
3.1. A stochastic model with four cell types. The stochastic model proposed in [4] for
tumor growth under ACT therapy consists in a four-dimensional continuous time Markov
process
Z(t) = (M(t), D(t), T (t), A(t)) ∈ N4
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Figure 4. Dynamics of the stochastic process: natural and therapy induced birth/death of
cells, T cell exhaustion, switches between the two types of melanoma cells and rates associated to
these events. M for differentiated melanoma cells; D for dedifferentiated melanoma cells; T for T
cells; A for cytokines TNFα. † symbolizes the death of cancer cells and cytokines; E symbolizes
the exhaustion of T cells. The orientation of the arrow indicates the sense of the evolution of
the population (an arrow with the initial and end points on the same population indicates a
reproduction in this population). The values above the arrows represent the rates [4].
with M(t) the population of differentiated melanoma cells, D(t) the population of dedif-
ferentiated melanoma cells, T (t) the population of active T cells, and A(t) the population
of cytokines TNFα at time t.
The growth phase of the disease (t < 70) is characterized by the reproduction and
death of melanoma cancer cells plus the natural switch between these two cancer cell
populations. At this stage, there are no active T cells nor cytokines TNFα (T (t), A(t)) =
(0, 0). The evolution of M(t) and D(t) is modeled by birth and death processes [19]
including additional terms modeling the switches between the two cancer cell populations.
Initial conditions are (M(0), D(0)) = (M0, 0). The control mice are uniquely modeled by
this dynamics.
At time t = 70 (beginning of treatment), a dose d70 of T cell stimulant is injected in the
system activating 2000 T cells (T (70) = 2000). Then, all cell populations and cytokines
(M(t), D(t), T (t), A(t)) evolve starting with initial conditions (M(70), D(70), 2000, 0).
The system models the evolution of differentiated melanoma cells M(t) (preys) in the
presence of active T cells T (t) (predators) as a predator-prey framework. An additional
natural exhaustion of active T cells is modeled by a simple death process. A deterministic
production of cytokines A(t) occurs at each T cell reproduction event while the death
of cytokines is modeled by a death process. An additional switch from differentiated to
dedifferentiated melanoma cell due to the presence of cytokines is also modeled. The ACT
group is modeled by the growth phase and this first treatment phase.
At time t = 160, an additional dose dRe of T-cell stimulant is injected for mice in
ACT+Re group activating again 2000 T cells. New initial conditions are (M(160), D(160),
T (160) + 2000, A(160)).
Figure 4 summarizes the dynamics of the process during the treatment phase (see Section
2.2 of [4] for more details).
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All the events in the stochastic model (birth, death and switch) occur after exponen-
tial waiting times regulated by rate parameters. The parameters bM and bD [Figure 4]
represent thus birth rates of differentiated (respectively dedifferentiated) melanoma cells
and correspond to the inverse of the average waiting time before observing the birth of a
new differentiated (respectively dedifferentiated) melanoma cell. Similarly, dM and dD cor-
respond to natural death rates of differentiated (respectively dedifferentiated) melanoma
cells while sMD and sDM represent respectively the switching rates from differentiated
melanoma cells to dedifferentiated one and the converse. Parameters bT and dT are re-
spectively the birth and exhaustion rates of active T cells. To a certain extent, bT can be
seen as an effective parameter corresponding to bT = b
0
T − d0T with b0T and d0T respectively
the therapy induced birth and exhaustion rates of active T cells. Indeed, differentiated
melanoma cells secrete a substance that exhausts active T cells with a rate d0T in addition
to their natural exhaustion rate dT . The therapy induced death of differentiated melanoma
cells is regulated by rate parameter tT while dA corresponds to the natural death rate of
cytokines TNFα. The product l
prod
A × bT represents the production rate of cytokines in-
duced by the therapy and sA is associated to the additional switching from differentiated
to dedifferentiated melanoma cells induced by cytokines.
We estimate the above described parameters as well as the initial quantity M0 of differ-
entiated melanoma cells which value is not fixed from one mouse to another.
3.2. Deterministic limit of the stochastic model. The stochastic model converges in
the limit of large population of cells to the solution of the following deterministic differential
system: 
n˙M = (bM − dM)nM − sMDnM + sDMnD − sAnAnM − tTnTnM
n˙D = (bD − dD)nD + sMDnM − sDMnD + sAnAnM
n˙T = −dTnT + bTnMnT
n˙A = −dAnA + lprodA bTnMnT
(3.1)
with initial condition (nM0 , nD0 , nT0 , nA0). A precise statement of this fact is given in [4].
Quantity nX(t) ∈ R (with X = M, D, T or A) represents the quantity of X at time t and
n˙X represents the variation of this quantity along time. Note that we work in this paper on
a simplified version of the initial model [4]. Some competition terms were removed as they
cannot be estimated from the data. Indeed, mice are killed before the tumor size (number
of cancer cells) reaches the (non trivial) fixed point regulated by the competition terms.
To avoid the problem of identifiability, new parameters are introduced: rM = bM − dM
and rD = bD − dD. To ease the notations, we set dM = dD = 0 (rM = bM and rD = bD),
keeping in mind that only the difference between birth and death rates of melanoma cells
can be estimated from the data.
The different phases of the therapy are similar to the ones of the stochastic model.
During the growth phase (t < 70), only populations of cancer cells nM(t) and nD(t) evolve
(nT (t), nA(t)) = (0, 0). All parameters associated with the treatment are then equal to
zero. At time t = 70, the quantity of active T cells is set as nT (70) = d70. The four
populations of cells (nM(t), nD(t), nT (t), nA(t)) evolve. The model (3.1) corresponds to
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the dynamics of the ACT group. For ACT+Re group, an additional quantity of active T
cells is added in the system at time tRe = 160 (nT (160) = nT (t) + dRe).
4. Estimation of the division-, death- and switch-rates based on the
experimental data
4.1. Mixed Effects Model for tumor growth under treatment. The parameters
are estimated by analyzing the three groups simultaneously. We use a Nonlinear Mixed
Effects regression Model (NLMEM) to take into account the inter-mice variability [27].
Parameter estimation with NLMEMs is difficult since the likelihood function does not
have an explicit form. When the regression function of the NLMEM is the stochastic
model, the high dimension of the event space prevents to compute the likelihood. Thus,
we choose to perform the parameter estimation based on the maximization of the likelihood
function of the deterministic model (3.1).
Let us define yi = (yi1, . . . , yini) where yij is the (noisy) measurement of the tumor
diameter value for mouse i at time tij, i = 1, . . . , N , j = 1, . . . , ni, and set y = (y1, . . . , yN).
The NLMEM is defined by:
yij = f(ψi, tij) + ij, (4.1)
ψi = µdi exp{ηi  di},
where  denotes component-wise multiplication and
µ = (rM , rD, sMD, sDM , nM0 , bT , dT , tT , sA, dA, l
prod
A ) is a vector of fixed effects;
di = ( 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0 ) when i is a control individual;
di = ( 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 ) when i is a treated individual;
i = (i1, . . . , ini) ∼ N (0, σ2Ini) represents the residual error
ηi = (η
i
rM
, ηirD , η
i
sMD
, ηisDM , η
i
nM0
, ηibT , η
i
dT
, ηitT , η
i
sA
, ηidA , η
i
lA
) ∼ N (0,Ω)
ηi is a vector of random effects independent of i ; ψi represents the vector of individual
regression parameters;
f(ψi, t) = (nM(ψi, t) + nD(ψi, t))
1
3
is describing the tumor diameter (up to some constant), with nM and nD being solution
of the nonlinear system (3.1); σ2 is the residual variance; Ini the identity matrix of size
ni; Ω the variance matrix of the random effects quantifying variability between mice. We
note θ = (µ,Ω, σ2) the parameters to be estimated.
A biological constraint states that the natural switch rate from a dedifferentiated melanoma
cell to a differentiated melanoma cell (sDM) is greater than the rate in the other direc-
tion (sMD) [21]. This constraint is taken into account by estimating sDMp such that
sDM = sDMp + sMD with sDMp > 0.
4.2. Parameter estimation using SAEM algorithm. The SAEM-MCMC algorithm
which combines the Stochastic Approximation Expectation Maximization algorithm [11]
with a Markov chain Monte Carlo procedure adapted to censored data [20, 32], imple-
mented under the software MONOLIX [23], is used to estimate the model parameters.
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ρ ρpop estimation (r.s.e (%)) ωρ estimation (r.s.e (%))
rM 0.09 (4) 0.10 (34)
rD 0.05 (10) 0.35 (20)
sMD < 0.01 (118) 0 (-)
sDMp < 0.01 (-) 0 (-)
nM0 0.08 (28) 0.58 (29)
bT < 0.01 (16) 0 (-)
dT 0.02 (34) 1.07 (27)
tT 1.33 (55) 1.03 (48)
sA 77 (37) 0 (-)
dA 0.03 (-) 0.09 (181)
lprodA 0.19 (93) 3.23 (25)
σ 0.44 (6) 0.03
Table 1. Estimated parameters for the final model: population mean ρpop and
inter-mice standard deviation ωρ for the log-normal distribution ρi = ρ
pop exp{ri},
ri ∼ N (0, ω2ρ), where ρ ∈ {rM , rD, sMD, sDMp , nM0 , bT , dT , tT , sA, dA, lprodA }. r.s.e
= standard errorestimation × 100 (in brackets). ωρ = 0 for parameters without random effect
and (-) means that the standard error is not estimated (the parameter is fixed).
We first proceed to model selection through likelihood ratio tests. We start with
the model having random effects on all parameters. Likelihood ratio tests lead to the
model given by {ηirM 6= 0, ηirD 6= 0, ηilA 6= 0, ηitT 6= 0, ηidT 6= 0, ηidA 6= 0, ηinM0 6= 0}.
Then, effect of the categorical covariate group denoted by G is tested on the fixed ef-
fects ρ ∈ {rM , rD, sMD, sDMp , nM0 , bT , dT , tT , sA, dA, lprodA }. ACT group is taken as reference
group, G = {ACT*, ACT+Re, CTRL}. Tests results showed that none of the parameters
is function of the covariate group G, i.e., the model captures the differences between groups
well enough without the help of an additional covariate. Thus, we take as final model the
one after likelihood ratio tests. We estimate the Fisher Information Matrix (F.I.M.) and
the associated standard errors for this model. In order to simplify the estimation of the
F.I.M (very difficult numerically here), we fix the mean of population parameters dA and
sDMp to their estimated values. Table 1 contains the estimates and the associated standard
errors of the final model, Figure 5 (and Figures 11, 12 in Appendix) show its individual
fits and Figures 13, 14, 15 in Appendix are used for evaluating the model performance.
4.3. The three mice groups are well fitted with the model. Data are well fitted,
growth and treatment phases are well enough captured despite the presence of censored
data (Figures 5, 11, 12). Indeed, the tumor growth phase is well fitted for CTRL mice
as well as for treated mice (before the beginning of therapy). Treatment effect in tumor
size dynamics from the 70th day is also well highlighted in both ACT and ACT+Re
groups. Furthermore, the restimulation effect is well marked in the tumor size dynamics
for ACT+Re mice. Another positive point of the model is that no additional covariate
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Figure 5. Individual fits for some mice from the different groups. The blue
+ marks represent no censored observations, the red asterisk symbols the
censored observations, the green line the fitted tumor size dynamics
was needed to distinguish the mice groups. Note that due to numerical difficulties, the
calculation of the effect of covariate G on parameters tT and sMD could not be completed.
We decided to keep the current model since, with fewer parameters, it leads to satisfactory
results.
Overall, the standard errors are satisfactory as well as the other validation elements in the
Appendix like Figure 13 (observations versus predictions), Figure 15 (SAEM convergence)
or Figure 14 (Visual Predictions Check (VPC)).
4.4. Biological relevance of the switching rate parameter. From a biological point
of view, an important fact is that the switching rate from differentiated melanoma cells to
dedifferentiated ones sA is expected to be higher than the killing rate of differentiated cells
by T cells tT [1]. This is corroborated by the estimated parameters (sA > tT , see Tables
1). Note that the calibration of model parameters in [4] led to tT much greater than sA.
Thus, by confirming this relation expected by biologists, the parameters estimated in this
paper lead us in a more realistic model.
5. Relapse due to T cell exhaustion
T cell exhaustion is a cause of relapse due which was highlighted in [4]. It is defined
by the stochastic event {T (t) ≤ S, t ≤ tF} where S is the exhaustion threshold and
t ≤ tF a condition for exhaustion to occur in a finite time. The complete T cell exhaustion
(S = 0) is a phenomenon which can only occur in the stochastic system: when the T cell
population is low enough, the stochastic fluctuations can drive it to extinction, whereas
PARAMETER ESTIMATION IN A STOCHASTIC MODEL FOR IMMUNOTHERAPY 11
the T cell population can never vanish in the deterministic limiting system. This follows
from the analyticity of the solutions to (3.1), given that T (70) > 0.
5.1. Very small T cell exhaustion probability for population parameters. We
want to estimate the exhaustion probability p = P(T (t) ≤ S, t ≤ tF ). Let u = 1T (t)≤S.
Using the intuitive Monte Carlo method, T cell exhaustion probability is estimated by
pˆ =
∑NT
k=1 uk/NT with NT the total number of simulations. However, depending on the
values of the model parameters, the exhaustion threshold S may be difficult to reach
leading sometimes to very small probabilities. Monte Carlo method thus requires a large
number NT of simulations when the probability p is very small. This method is therefore
not suitable for estimating the probability of T cell exhaustion because the variance will
diverge when the probability tends to zero for a reasonable value of NT [24]. To reduce the
variance for very small probabilities estimation, an alternative is the Importance Splitting
(IS) algorithm designed for rare event probability estimation [9, 18, 24]. Indeed, IS grad-
ually calculates the probability of reaching the threshold S (the rare event) through the
calculation of the probability of reaching intermediate thresholds easier to reach than S.
Thus, the probability P(T (t) ≤ S, t ≤ tF ) is calculated according to the splitting principle
by
P(T (t) ≤ S, t ≤ tF ) =
m∏
k=1
pk (5.1)
with p1 = P(Tt ≤ S1, t ≤ tF ) and pk = P(Tt ≤ Sk | Ts ≤ Sk−1, s ≤ t ≤ tF ) for k = 2, . . . ,m.
The Sk (k < m) are the intermediate thresholds and Sm = S the exhaustion threshold.
The IS algorithm consists at each iteration k in the simulation of NT trajectories of the
process Tt and the estimation (by Monte Carlo) of the intermediate probability pk by con-
sidering the number NSk of trajectories which reach the intermediate threshold Sk before
time tF : pˆk =
NSk
NT
. To pass from iteration k to iteration k + 1, NT trajectories are sam-
pled from the NSk trajectories having reached the threshold Sk (by allowing replacement
in the sampling) and run the NT new trajectories in order to reach the next threshold
Sk+1. In our setting, we consider that there is T cell exhaustion at time t when the quan-
tity of T cells at t reaches S5 = 0. Then, we define four other intermediate thresholds
S1 = 7× 10−5 (or 0.35% of the initial quantity of active T cells), S2 = 5× 10−5 (0.25% of
T (70)), S3 = 3 × 10−5 (0.15% of T (70)), and S4 = 2 × 10−5 (0.1% of T (70)). We set NT
to 1000.
First of all, the T cell exhaustion probability estimated by the IS algorithm is ”zero”
(very close to absolute zero) for both individual and population parameters in both ACT
and ACT+Re groups. Figure 6 shows the dynamics of cancer cells, T cells, and cytokines
for population parameters in the ACT group. For these sets of parameter values, T cells
thus survive and continue to kill differentiated cells (whose number does not explode).
However, the therapy enhanced the production of dedifferentiated melanoma cells (not
killed by T cells) leading to a large increase in their number. Furthermore, since the tumor
is formed by the sum of differentiated and dedifferentiated melanoma cells, we observe a
regrowth in tumor size (relapse). Thus, we highlight the existence of sets of biological
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Figure 6. Number of cells (rescaled by K = 105) along time (days) using population param-
eters of ACT mice. Topleft: differentiated melanoma cell (in blue), Topright: dedifferentiated
melanoma cell (in red), Bottomleft: T cell (in green) and Bottomright: cytokine TNFα (in black).
Maximum number of stochastic events (natural or therapy induced birth, death, switches): 300
millions. Beginning of the treatment is indicated by a vertical orange line at the 70th day.
Scenario: T cell survive.
parameters (estimated from biological data) for which a relapse due to the dedifferentiated
melanoma cells occurred.
5.2. Evolution of T cell exhaustion probability with respect to therapy param-
eters. Some of the estimated parameters have a random effect. We study the T cell
exhaustion by naturally taking into account their distribution. We start with the death
rate of T cells dT which is one of the parameters which is the most relevant for the therapy.
We thus estimate the T cell exhaustion probability as a function of dT in its estimation
range (dT ∈ dpopT exp{ηidT }, ηidT ∼ N (0, ω2dT )) when the other parameters are fixed to their
estimated population values (still in ACT group). The T cell exhaustion probability in-
creases with dT , and even reaches non negligible values (Figure 7). Furthermore, when
the T cell exhaustion occurred, we observe an explosion of the number of differentiated
melanoma cells (for a relatively small dedifferentiated cell population) leading to a relapse.
This corroborates the hypothesis in [4] which asserts that there exist biological parameters
for which the probability of disease relapse due to T cell exhaustion is non negligible.
Note that the computation of T cell exhaustion probability (for one given set of param-
eter values) requires NT = 1000 simulations of the stochastic model for each of the m = 5
thresholds of IS algorithm. Furthermore, each trajectory (among the four composing one
simulation) can contain up to 100 millions of stochastic events. This stochastic approach
is therefore very expensive in computing time. For example, the average time to calculate
the exhaustion probability for dT = 0.1964 (quantile of order 99%) is approximately 100
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Figure 7. Evolution of T cell exhaustion probability (solid line in brown) and deterministic
global minimum of T cells (dashed line in green) according to the death rate of T cells (dT ) in the
ACT group (the other parameters are fixed to their estimated population mean). For each value
of dT , the T cell exhaustion probability is computed 5 times and the mean is represented with an
error bar (corresponding to mean ± standard deviation). The solid vertical lines in red indicate
respectively (from left to right) the quantiles of order 5%, 50%, 95%; the dashed vertical lines in
orange represent the quartiles and the dotted vertical lines in purple represent respectively the
quantiles of order 1%, 50%, 99%.
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Figure 8. Number of cells (rescaled by K = 105) along time (days) using population pa-
rameters of ACT mice and dT = quantile of order 99% of dTi . Topleft: differentiated melanoma
cell (in blue), Topright: dedifferentiated melanoma cell (in red), Bottomleft: T cell (in green)
and Bottomright: cytokine TNFα (in black). Maximum number of stochastic events (natural
or therapy induced birth, death, switches): 300 millions. The beginning of the treatment is
indicated by a vertical orange line at the 70th day. Scenario: T cell exhaustion.
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Figure 9. Evolution of the deterministic global minimum of T cells (solid line in green)
according to the parameters having a random effect in Table 1 (in ACT group). For each
subfigure, the other parameters are fixed to their estimated population values. Top-left: tT ,
Top-right: lprodA , Middle-left: dA, Middle-right: rM , Bottom-left: rD, Bottom-right: nM0 . The
solid vertical lines in red indicates respectively (from left to right) the quantiles of order 5%,
50%, 95% and the dashed vertical lines in orange represents the quartiles.
hours (using 3 cores, with 7GB of memory per core). However, this stochastic approach
allows us to highlight a link between the probability of T cell exhaustion and the depth
of the corresponding T cell deterministic minimum (Figure 7). Indeed, we note that the
lower the deterministic minimum the greater the probability of T cell exhaustion. We thus
exploit this relation to cheaper study the effect of the other parameters having a random
effect on the T cell exhaustion phenomenon. Thus, Figure 9 shows the evolution of the
depth of the T cell deterministic minimum according to these parameters.
Figures 7 and 9 allow us to get a first idea of how the evolution of the deterministic
minimum (indirectly the probability of T cell exhaustion) is affected by a parameter with
random effect (the others parameters being fixed to their population mean). We observe
that the minimum becomes deeper and deeper when the parameters like dT , tT and l
prod
A ,
which are strongly related to therapy, evolve. On the other hand, the minimum seems
to increase when disease parameters like rM , rD and nM0 increase. We observe similar
dynamics with dA. Given these observations, we can expect that the joint variation of
these parameters will lead us to interesting therapeutic scenarios.
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6. Treatment optimization to minimize the probability of relapse due to
T cell exhaustion
6.1. Criteria to optimize treatment doses and restimulation times. The kind of
relapse we can act on without changing the medical setup is the relapse due to T cell
exhaustion. We thus want to minimize the probability of T cell exhaustion, i.e. to keep
the minimum of T cell trajectory as high as possible in order to avoid the stochastic
fluctuations cross the exhaustion threshold S = 0. Treatment parameters to be optimized
are the treatment dose d70, the retreatment time tRe and dose dRe. Optimization is done
with the deterministic model by exploiting the link between the exhaustion probability and
the depth of the T cell deterministic minimum (Figure 7). Cost function (to be maximized)
is defined by
g = min{nT (t), t ≤ tF} (6.1)
with nT (t) solution of deterministic system (3.1) and tF a fixed finite time. Note that g
depends on all the model parameters through nT (t). In the following, we will optimize the
therapy by maximizing g over different subsets of treatment parameters.
To take into account random effects in the optimization, we consider some specific
quantiles of their distribution. To reduce the size of the problem, we focus on the T-
cell related parameters dT (natural death rate of T cells), tT (therapy induced death
rate of the differentiated melanoma cells) and lprodA (which, multiplied by bT , leads to
the therapy induced production rate of the cytokines). We then set the value of the
natural death rate dA of cytokines to its population value since it is less related to T cells
compared to the three previous treatment parameters and seems to have less effect on
the minimum (Figure 9). We also set the value of the disease parameters rM and rD to
their population mean assuming that these are disease-specific parameters that are less
under our control. However, we consider different quantiles of the distribution of nM0 , a
disease-related parameter. Indeed, nM0 allows to characterize the stage of the disease and
is therefore a relevant variable to present our results. In summary, we set rM , rD and dA
to their population values and consider specific quantiles for dT , tT , l
prod
A and nM0 .
We consider two optimization procedures: the first is performed on ACT group and
leads in the optimal treatment dose d
opt∗
70 . Here we consider the dependence of function
g on the treatment dose d70 (g = g(d70)). The treatment is optimized by the following
criteria:
d
opt∗
70 = arg max
d70∈[dmin,dmax]
g(d70). (6.2)
The second optimization procedure is performed on ACT+Re group (for g = g(d70, dRe, tRe))
and provides the optimal treatment dose d
opt∗∗
70 , the optimal retreatment dose d
opt
Re and the
optimal retreatment time toptRe
[d
opt∗∗
70 , d
opt
Re , t
opt
Re ] = arg max
(d70,dRe,tRe)∈D
g(d70, dRe, tRe), (6.3)
where D = [dmin, dmax]× [dRemin, dRemax]× [tRemin, tRemax].
6.2. Computation of the optimal values.
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ρ
Quantiles
q5 q25 q50 q75 q95
dT < 0.01 0.01 0.02 0.03 0.09
tT 0.24 0.66 1.33 2.66 7.24
lprodA < 0.01 0.02 0.19 1.71 39.37
nM0 0.03 0.05 0.08 0.12 0.21
Table 2. Quantile values for parameters having random effects considered in
treatment optimization. qα represents the quantile of order α%.
6.2.1. Methodology. We take into account in optimization procedure the distribution of
random effects ηiρ ∼ N (0, ωρ), for ρ ∈ {dT , tT , lprodA , nM0}, by considering respectively the
quartiles and the quantiles of order 5%, 50%, 95% of ρi = ρ
pop exp{ηiρ}. These quantile
values are given in Table 2. The other parameters are set at their population mean.
Furthermore, we consider the following initial values: t0 = 0 representing the initial time;
nM0 ∈ {quantiles of nM0i} indicating different initial values of differentiated melanoma
cells (or different stages of the disease); D0 = 0 the initial quantity of dedifferentiated
melanoma cells; A0 = 0 the initial quantity of TNFα; d
initial
70 = 0.02 the initial stimulation
dose, dinitialRe = 0.02 the initial restimulation dose and t
initial
Re = 160 the initial restimulation
time.
Treatment dose optimization interval [dmin, dmax] is set at [0.005, 0.04] for both ACT
and ACT+Re groups and retreatment dose optimization interval [dRemin, d
Re
max] at [0, 0.04]
for ACT+Re group (such that doptRe = 0 when d
opt∗∗
70 is enough to avoid T cell exhaustion
to occur before time t ≤ tF ). Indeed, from an experimental point of view, the initial dose
dinitial = 0.02 is well chosen for good tumor control [1]. This leads us to set dmin, dmax,
dRemin and d
Re
max not too far from d
initial. Similar considerations lead us to set the retreatment
time optimization interval as [tRemin, t
Re
max] = [130, 190]. Time tF is set as tF = 300 in ACT
group and as tF = 400 in ACT+Re group (based on experimental data of Figure 3).
Optimal values are computed from the plots of g as a function of treatment parameters
for a fixed set {tT , dT , lprodA , nM0} of parameter values (Figure 10).
6.2.2. Optimal treatment values using quartiles of tT , dT , l
prod
A , nM0. We consider the
34 = 81 sets of parameter values corresponding to the three quartiles for each of the four
parameters tT , dT , l
prod
A , and nM0 . Among these sets of parameter values, none actually
presents an increased risk of T cell exhaustion. Indeed, the smaller deterministic minimum
observed among these 81 sets is around 1.4 × 10−3 in both ACT and ACT+Re groups.
This value of the deterministic minimum corresponds to a T cell exhaustion probability
of zero by referring to Figure 7. However, optimizing the treatment to keep the T cell
minimum as high as possible is still beneficial since it allows to further delay the possible
relapse due to T cell exhaustion. Table 3 presents in its column ACT the optimization
results for criterion (6.2) (for seven sets of parameter values among the 81), and in column
ACT+Re the corresponding optimal parameter values for criterion (6.3).
6.2.3. Optimal treatment values using quantiles of order 5%, 50%, 95% of tT , dT , l
prod
A ,nM0.
Using the quantiles of order 5%, 50%, 95% of tT , dT , l
prod
A and nM0 , we identify among the
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tT , dT , l
prod
A , nM0 par. ACT g
opt
ACT ACT+Re g
opt
ACT+Re
q25, q25, q25, q25
dopt70 0.04 4.00× 10−2 0.04 4.00× 10−2
doptRe - 0.00
toptRe - 130
q25, q75, q50, q25
dopt70 0.012 6.76× 10−3 0.04 1.0× 10−2
doptRe - 0.012
toptRe - 130
q75, q25, q25, q25
dopt70 0.033 2.87× 10−2 0.04 3.35× 10−2
doptRe - 0.019
toptRe - 130
q75, q50, q25, q75
dopt70 0.026 2.60× 10−2 0.033 2.78× 10−2
doptRe - 0.019
toptRe - 130
q75, q50, q75, q25
dopt70 0.04 7.61× 10−3 0.04 1.62× 10−2
doptRe - 0.033
toptRe - 130
q75, q75, q25, q50
dopt70 0.026 1.70× 10−2 0.026 1.70× 10−2
doptRe - 0.00
toptRe - 130
q75, q75, q75, q25
dopt70 0.04 1.59× 10−3 0.033 4.57× 10−3
doptRe - 0.04
toptRe - 130
Table 3. Summary table of optimization results using quartiles of tT , dT , lprodA and
nM0 in both ACT and ACT+Re groups. Column g
opt
ACT corresponds to g(d
opt∗
70 ) and
goptACT+Re to g(d
opt∗∗
70 , d
opt
Re , t
opt
Re ). We consider six discrete values with a regular discretiza-
tion for each treatment parameter: d70, dRe ∈ {0.005, 0.012, 0.019, 0.026, 0.033, 0.040}, tRe ∈
{130, 142, 154, 166, 178, 190} (with an additional value of 0 for dRe to take into account the cases
where dRe = 0).
81 sets of parameter values 9 combinations of dT , tT , l
prod
A and nM0 leading to an increased
risk of T cell exhaustion (the same sets of parameters for both ACT and ACT+Re mice).
For that purpose, we set the threshold of T cell exhaustion risk at S1 = 7× 10−5, i.e., the
first intermediate threshold of our IS algorithm. S1 represents a value beyond which we
can start to worry that stochastic fluctuations lead to the T cell exhaustion.
Figures 10a and 10b show optimal treatment parameters corresponding to two sets of
parameter values for optimization criterion (6.2) (Figure 10a presents a risk of T cell
exhaustion, Figure 10b is without an exhaustion risk). Figures 10c and 10d show the
optimization results for the same two sets of parameters for criterion (6.3). Table 4 presents
the optimization results for the nine sets of parameter values presenting an increased risk
of exhaustion. The column ACT corresponds to optimization criterion (6.2) and column
ACT+Re to criterion (6.3).
Note that parameter values leading to an increased risk of T cell exhaustion mainly
correspond to high values of parameters dT and l
prod
A as shown for their quantile of order
95% in Figure 10. The risk of T cell exhaustion persists for values of dT and l
prod
A smaller
than their quantile of order 95% (for the same threshold S1). For example, for the quantile
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Figure 10. T cell minimum according to treatment parameters using quantiles qα(ρ),
α ∈ {5, 50, 95}, ρ ∈ {tT , dT , lprodA , nM0}. Values of {tT , dT , lprodA } are given in captions of sub-
figures. In ACT group (Figures 10a, 10b): solid curve in cyan (q5(nM0)), dashed curve in
purple (q50(nM0)), dotted curve in yellow (q95(nM0)). Vertical lines indicate the optimal doses
d
opt∗
70 for the corresponding nM0 . In ACT+Re group (Figures 10c, 10d): one curve for one dis-
crete retreatment time tRe ∈ {(130, solid in black), (142, dashed in red), (154, dotted in green),
(166, dotdashed in blue), (178, longdashed in cyan), (190, twodashed in purple)}. Vertical lines
indicate the optimal doptRe for the corresponding values of tRe. Here, Figures 10c and 10d are for
the optimal d
opt∗∗
70 (d70 ∈ {0.005, 0.012, 0.019, 0.026, 0.033, 0.040}) Figures 10a and 10c present
an exhaustion risk, Figures 10b and 10d are without exhaustion risk (for a risk threshold at S1).
of order 90% of dT and l
prod
A (and tT ), the value of g(d
initial
70 ) is equal to 3.45 × 10−5,
4.20× 10−5 and 5.74× 10−5 respectively for nM0 equal to its quantiles of order 20%, 50%
and 90%.
6.3. Discussion on optimized doses and restimulation times.
6.3.1. Higher treatment doses and earlier restimulation times are not always optimal pa-
rameters. With both the quartiles and the quantiles of order 5%, 50%, 95% of tT , dT , l
prod
A ,
and nM0 , we observe different therapeutic scenarios. First of all, we note that for most of
the sets of parameter values, the optimal doses are the maximal ones: dopt70 , d
opt
Re = dmax
(see Figure 10a or Figures 16, 17, 19 in Appendix) and the optimal retreatment time is
the minimal one toptRe = t
Re
min (See t
opt
Re values in Table 3). Thus, we can expect that higher
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tT , dT , l
prod
A , nM0 par. ACT g
opt
ACT g
initial
ACT ACT+Re g
opt
ACT+Re g
initial
ACT+Re
q5, q95, q95, q5
dopt70 0.04 8.29× 10−7 6.77× 10−7 0.019 1.92× 10−5 4.45× 10−6
doptRe - 0.04
toptRe - 142
q5, q95, q95, q50
dopt70 0.04 1.36× 10−6 1.10× 10−6 0.033 3.49× 10−5 4.73× 10−6
doptRe - 0.04
toptRe - 142
q5, q95, q95, q95
dopt70 0.04 2.33× 10−6 1.86× 10−6 0.04 4.66× 10−5 5.22× 10−6
doptRe - 0.012
toptRe - 142
q50, q95, q95, q5
dopt70 0.04 7.99× 10−7 6.61× 10−7 0.019 1.87× 10−5 4.44× 10−6
doptRe - 0.04
toptRe - 142
q50, q95, q95, q50
dopt70 0.04 1.33× 10−6 1.08× 10−6 0.033 3.40× 10−5 4.72× 10−6
doptRe - 0.04
toptRe - 142
q50, q95, q95, q95
dopt70 0.04 2.29× 10−6 1.83× 10−6 0.04 4.66× 10−5 5.20× 10−6
doptRe - 0.019
toptRe - 142
q95, q95, q95, q5
dopt70 0.04 6.56× 10−7 5.78× 10−7 0.019 1.64× 10−5 4.38× 10−6
doptRe - 0.04
toptRe - 142
q95, q95, q95, q50
dopt70 0.04 1.16× 10−6 9.84× 10−7 0.033 2.99× 10−5 4.65× 10−6
doptRe - 0.04
toptRe - 142
q95, q95, q95, q95
dopt70 0.04 2.09× 10−6 1.72× 10−6 0.04 4.63× 10−5 5.13× 10−6
doptRe - 0.019
toptRe - 142
Table 4. Summary table of optimization results using quantiles qα(ρ), α ∈ {5, 50, 95},
ρ ∈ {tT , dT , lprodA , nM0} in both ACT and ACT+Re groups (for parameters leading to
ginitial ≤ S1). Column goptACT corresponds to g(dopt∗70 ), column ginitialACT to g(dinitial) while column
goptACT+Re corresponds to g(d
opt∗∗
70 , d
opt
Re , t
opt
Re ) and g
initial
ACT+Re to g(d
initial, dinitial, tinitialRe ). We con-
sider six discrete values with a regular discretization for each treatment parameter: d70, dRe ∈
{0.005, 0.012, 0.019, 0.026, 0.033, 0.040}, tRe ∈ {130, 142, 154, 166, 178, 190} (with an additional
value of 0 for dRe to take into account the cases where dRe = 0).
treatment dose values would further delay the T cell exhaustion or that an earlier restim-
ulation would reduce the risk of an early exhaustion. However, the treatment parameters
are optimized over optimization intervals which take into account biological considerations
as explained in Section 6.2.1. It may thus be experimentally non trivial to go beyond those
intervals.
Observe that, for most rate parameters (like in Figure 27 in Appendix), the larger
dose, the deeper the T cell global minimum, therefore the higher the probability of T cell
exhaustion.
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We also observe for some parameter values (Figure 19 or sixth lines in Table 3) that
the optimal restimulation dose is zero: doptRe = 0. In this cases, the treatment dose d70 is
sufficient to keep the minimum high enough.
Finally, for an important number of sets of parameter values (like in Figures 10b and
10c or in Figures 18, 23, 24, 25 in Appendix) we find optimal parameters well located
inside the optimization interval (dmin < d
opt
70 , d
opt
Re < dmax, t
Re
min < t
opt
Re < t
Re
max). In these
cases our results provide treatment doses and restimulation times which differ from the
already tested experimental ones and which lead to a more efficient therapy.
6.3.2. Treatment optimization is more efficient on ACT+Re mice. Optimization benefits
can be evaluated by calculating the probability of T cell exhaustion using the IS algorithm.
As the function g (denoting the value of the deterministic minimum of the T cell popula-
tion) is related to the exhaustion probability, we compare the values of g before and after
optimization.
Let ImpACT+Re = (g
opt
ACT+Re − ginitialACT+Re)/goptACT+Re denote the improvement in ACT+Re
group after treatment optimization and ImpACT = (g
opt
ACT − ginitialACT )/goptACT the improvement
in ACT group (for the parameters used to compute ImpACT+Re). For all the optimized
treatment parameters, the two improvements are positive (ImpACT+Re ≥ 0, ImpACT ≥
0). Moreover, the difference ImpACT+Re − ImpACT is always positive with a mean value
equal to 65.7 ± 4.8% for the nine sets of rate parameters presenting an increased risk of
T cell exhaustion (Table 4). Thus, the best improvements are noted in ACT+Re mice
compared to ACT mice. This remark makes sense since ACT+Re mice have benefited
from restimulation, which boosts the effects of optimization.
Note however that the treatment optimization only minimizes the risk of T cell exhaus-
tion for these nine sets of parameter values. Indeed, the risk does not vanish completely
(for the threshold S1) as it can be seen in Table 4 (g
opt is still smaller than S1). Considering
wider optimization intervals could improve the results provided that the new limits remain
biologically reasonable.
6.3.3. The larger nM0, the faster the tumor growth even for higher treatment doses. It has
been biologically observed [1] that when the tumor size exceeds a certain threshold at the
beginning of the treatment (t = 70), the tumor control is less efficient even if more T cells
are stimulated. Figure 26 (in Appendix) representing the tumor size dynamics for different
values of nM0 supports this observation: the larger nM0 , the larger tumor size at t = 70,
the faster the tumor growth (even for d70 = d
opt∗
70 = dmax). Large treatment doses d70 do
not slow down much the evolution of the tumor size for large initial value of differentiated
melanoma cells.
7. Conclusion
In cancer treatment, resistance to therapy is a major problem. Understanding the mech-
anism of this resistance is then crucial. The parameter estimation for the mathematical
model of [4] for melanoma cancer immunotherapy using biological data from [21] was es-
sential in achieving this goal. Indeed, the estimated parameters lead to an accurate model
which is necessary for further quantitative studies. We use these parameters to simulate
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realistic stochastic phenomena arising in the therapy and to highlight the existence of sets
of biological parameters leading to each of the types of relapses identified by the authors
of [4]. Moreover, we were able to quantitatively estimate the probability of relapse due to
the T cell exhaustion which allows to evaluate the quality of the treatment.
In addition, we confirmed two important conjectures from the authors of [21]. First,
the experimental data [21] suggest that the switch rate sA induced by cytokines should be
higher than the rate tT at which T cells kill differentiated melanoma cells. Our estimated
parameters support this conjecture, while calibrated parameters in [4] led to sA < tT . We
thus provide a more realistic version of the model.
Second, biological observations [1] show that when the tumor size exceeds a certain thresh-
old at the beginning of the treatment (t = 70), the tumor control is less efficient even if
more T cells are stimulated. We indeed highlight the low effect of high treatment doses
d70 when the tumor size reaches a certain level at the beginning of the treatment.
With the estimated parameters, we optimize the treatment protocol using the determin-
istic system due to the high computational cost in the stochastic setting. We perform the
optimization by plotting the value of the minimum of the T cell population as a function
of treatment parameters (by considering some reasonable discretization of the parameter
space). By linking the value of the minimum to the exhaustion probability of T cells, we
provide optimal treatment doses and (re)stimulation time(s) which minimize the probabil-
ity of relapse due to T cell exhaustion.
An alternative to the use of deterministic system would be the use of a diffusion ap-
proximation of the stochastic model. Thus, a stochastic aspect would be included in the
problem while remaining reasonable in computational costs. An interesting statistical
challenge, which is a work in progress, is the parameter estimation in this stochastic dif-
fusion approximation. The difficulties are mainly due to the predator-prey part and high
dimension.
In this paper, we focused on the relapse due to T cell exhaustion. However, the second
source of relapse due to dedifferentiated melanoma cells must also be resolved. There
are prospects to handle this problem also with modifications of the treatment protocol.
One solution may be to introduce another type of T cell that can kill the dedifferentiated
melanoma (see [4] for a theoretical study for a model for such a treatment protocol).
Another solution is to find a way to control the switching rate sA of differentiated melanoma
to dedifferentiated melanoma cells [15]. Indeed, if sA is well controlled in the therapy (and
if the number of dedifferentiated cells is finally zero or low enough to cause a relapse), then
the problem of complete healing of mice will come down to the control of T-cell exhaustion.
Thus, our work is a useful tool for new protocols of tumor treatment.
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A. Appendix
Note that the code used to simulate the stochastic dynamics has been written in C++
and ran under the software R [29] through the package Rcpp [13].
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Figure 11. Individual fits for the final model. The blue + marks repre-
sent no censored observations, the red asterisk symbols the censored obser-
vations, the green line the fitted tumor size dynamic.
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Figure 12. Individual fits for the final model. The blue + marks repre-
sent no censored observations, the red asterisk symbols the censored obser-
vations, the green line the fitted tumor size dynamic.
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Figure 13. predicted values versus observed values to assess the accuracy
of the final model. The blue points represents no censored observations,
the red asterisk symbols the censored observations.
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Figure 14. Prediction-corrected Visual Predictive Checks (pcVPC) for the
final model.
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Figure 16. T cell minimum according to treatment dose d70 in ACT group for tT = q25(tTi).
Top-figures: dT = q25(dTi) ; Middle-figures: dT = q50(dTi) ; Bottom-figures: dT = q75(dTi).
Left-figures: lprodA = q25(l
prod
Ai
) ; Middle-figures: lprodA = q50(l
prod
Ai
) ; Right-figures: lprodA =
q75(l
prod
Ai
). In each sub-figure: nM0 = q25(nM0i ) (solid curve in cyan); nM0 = q50(nM0i ) (dashed
curve in purple); nM0 = q75(nM0i ) (dotted curve in yellow). The vertical solid, dashed and
dotted lines indicate the optimal dose d
opt∗
70 for a given nM0 .
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Figure 15. SAEM convergence for the final model.
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Figure 17. T cell minimum according to treatment dose d70 in ACT group for tT = q50(tTi).
Top-figures: dT = q25(dTi) ; Middle-figures: dT = q50(dTi) ; Bottom-figures: dT = q75(dTi).
Left-figures: lprodA = q25(l
prod
Ai
) ; Middle-figures: lprodA = q50(l
prod
Ai
) ; Right-figures: lprodA =
q75(l
prod
Ai
).In each sub-figure: nM0 = q25(nM0i ) (solid curve in cyan); nM0 = q50(nM0i ) (dashed
curve in purple); nM0 = q75(nM0i ) (dotted curve in yellow). The vertical solid, dashed and
dotted lines indicate the optimal dose d
opt∗
70 for a given nM0 .
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
0.
02
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
0.
02
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
0.
02
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
6
0.
01
0
0.
01
4
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
3
0.
00
6
0.
00
9
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
40
0.
00
50
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
08
0.
00
14
0.
00
20
dose_70
m
in
 T
 c
el
l
Figure 18. T cell minimum according to treatment dose d70 in ACT group for tT = q75(tTi).
Top-figures: dT = q25(dTi) ; Middle-figures: dT = q50(dTi) ; Bottom-figures: dT = q75(dTi).
Left-figures: lprodA = q25(l
prod
Ai
) ; Middle-figures: lprodA = q50(l
prod
Ai
) ; Right-figures: lprodA =
q75(l
prod
Ai
).In each sub-figure: nM0 = q25(nM0i ) (solid curve in cyan); nM0 = q50(nM0i ) (dashed
curve in purple); nM0 = q75(nM0i ) (dotted curve in yellow). The vertical solid, dashed and
dotted lines indicate the optimal dose d
opt∗
70 for a given nM0 .
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Figure 19. T cell minimum according to treatment parameters in ACTRE group for
tT = q25(tTi); dT = q25(dTi); l
prod
A = q25(l
prod
Ai
); nM0 = q25(nM0i ). From top to bottom
and from left to right: d70 = 0.005, 0.012, 0.019, 0.026, 0.033, 0.040. In each subfigure: one
curve for one value of tRe ∈ {(130, solid in black), (142, dashed in red), (154, dotted in green),
(166, dotdashed in blue), (178, longdashed in cyan), (190, twodashed in purple)}. Vertical lines
indicate doptRe for the corresponding tRe. Values of d70, dRe and tRe maximizing g among the six
subfigures constitute the optimal treatment parameters. Here: d
opt∗∗
70 = 0.04, d
opt
Re = 0, t
opt
Re = 130.
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Figure 20. T cell minimum according to treatment parameters in ACTRE group for
tT = q75(tTi); dT = q50(dTi); l
prod
A = q75(l
prod
Ai
); nM0 = q25(nM0i ). From top to bottom
and from left to right: d70 = 0.005, 0.012, 0.019, 0.026, 0.033, 0.040. In each subfigure: one
curve for one value of tRe ∈ {(130, solid in black), (142, dashed in red), (154, dotted in green),
(166, dotdashed in blue), (178, longdashed in cyan), (190, twodashed in purple)}. Vertical lines
indicate doptRe for the corresponding tRe. Values of d70, dRe and tRe maximizing g among the six
subfigures constitute the optimal treatment parameters. Here: d
opt∗∗
70 = 0.04, d
opt
Re = 0.033, t
opt
Re =
130.
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Figure 21. T cell minimum according to treatment dose d70 in ACT group for tT = q5(tTi).
Top-figures: dT = q5(dTi) ; Middle-figures: dT = q50(dTi) ; Bottom-figures: dT = q95(dTi). Left-
figures: lprodA = q5(l
prod
Ai
) ; Middle-figures: lprodA = q50(l
prod
Ai
) ; Right-figures: lprodA = q95(l
prod
Ai
).In
each sub-figure: nM0 = q5(nM0i ) (solid curve in cyan); nM0 = q50(nM0i ) (dashed curve in
purple); nM0 = q95(nM0i ) (dotted curve in yellow). The vertical solid, dashed and dotted lines
indicate the optimal dose d
opt∗
70 for a given nM0 .
0.005 0.015 0.025 0.035
0.
00
5
0.
02
0
0.
03
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
02
0
0.
03
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
0.
02
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
02
0
0.
03
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
5
0.
01
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
1
0.
00
3
0.
00
5
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
0
0.
01
0
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
0.
00
05
0.
00
15
dose_70
m
in
 T
 c
el
l
0.005 0.015 0.025 0.035
5.
0e
−0
7
1.
5e
−0
6
dose_70
m
in
 T
 c
el
l
Figure 22. T cell minimum according to treatment dose d70 in ACT group for tT = q50(tTi).
Top-figures: dT = q5(dTi) ; Middle-figures: dT = q50(dTi) ; Bottom-figures: dT = q95(dTi). Left-
figures: lprodA = q5(l
prod
Ai
) ; Middle-figures: lprodA = q50(l
prod
Ai
) ; Right-figures: lprodA = q95(l
prod
Ai
).In
each sub-figure: nM0 = q5(nM0i ) (solid curve in cyan); nM0 = q50(nM0i ) (dashed curve in
purple); nM0 = q95(nM0i ) (dotted curve in yellow). The vertical solid, dashed and dotted lines
indicate the optimal dose d
opt∗
70 for a given nM0 .
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Figure 23. T cell minimum according to treatment dose d70 in ACT group for tT = q95(tTi).
Top-figures: dT = q5(dTi) ; Middle-figures: dT = q50(dTi) ; Bottom-figures: dT = q95(dTi). Left-
figures: lprodA = q5(l
prod
Ai
) ; Middle-figures: lprodA = q50(l
prod
Ai
) ; Right-figures: lprodA = q95(l
prod
Ai
).In
each sub-figure: nM0 = q5(nM0i ) (solid curve in cyan); nM0 = q50(nM0i ) (dashed curve in
purple); nM0 = q95(nM0i ) (dotted curve in yellow). The vertical solid, dashed and dotted lines
indicate the optimal dose d
opt∗
70 for a given nM0 .
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Figure 24. T cell minimum according to treatment parameters in ACTRE group for
tT = q5(tTi); dT = q95(dTi); l
prod
A = q95(l
prod
Ai
); nM0 = q5(nM0i ). From top to bottom and
from left to right: d70 = 0.005, 0.012, 0.019, 0.026, 0.033, 0.040. In each subfigure: one
curve for one value of tRe ∈ {(130, solid in black), (142, dashed in red), (154, dotted in green),
(166, dotdashed in blue), (178, longdashed in cyan), (190, twodashed in purple)}. Vertical lines
indicate doptRe for the corresponding tRe. d70, dRe and tRe maximizing g among the six subfigures
constitute the optimal treatment parameters. Here: d
opt∗∗
70 = 0.019, d
opt
Re = 0.04, t
opt
Re = 142.
PARAMETER ESTIMATION IN A STOCHASTIC MODEL FOR IMMUNOTHERAPY 29
0.00 0.01 0.02 0.03 0.04
5.
0e
−0
6
1.
0e
−0
5
1.
5e
−0
5
2.
0e
−0
5
dRe
m
in
 T
 c
el
l
0.00 0.01 0.02 0.03 0.04
0e
+0
0
1e
−0
5
2e
−0
5
3e
−0
5
4e
−0
5
dRe
m
in
 T
 c
el
l
0.00 0.01 0.02 0.03 0.04
1e
−0
5
2e
−0
5
3e
−0
5
4e
−0
5
dRe
m
in
 T
 c
el
l
0.00 0.01 0.02 0.03 0.04
1e
−0
5
2e
−0
5
3e
−0
5
4e
−0
5
dRe
m
in
 T
 c
el
l
0.00 0.01 0.02 0.03 0.04
1e
−0
5
2e
−0
5
3e
−0
5
4e
−0
5
dRe
m
in
 T
 c
el
l
0.00 0.01 0.02 0.03 0.04
1e
−0
5
2e
−0
5
3e
−0
5
4e
−0
5
dRe
m
in
 T
 c
el
l
Figure 25. T cell minimum according to treatment parameters in ACTRE group for
tT = q5(tTi); dT = q95(dTi); l
prod
A = q95(l
prod
Ai
); nM0 = q95(nM0i ). From top to bottom and
from left to right: d70 = 0.005, 0.012, 0.019, 0.026, 0.033, 0.040. In each subfigure: one
curve for one value of tRe ∈ {(130, solid in black), (142, dashed in red), (154, dotted in green),
(166, dotdashed in blue), (178, longdashed in cyan), (190, twodashed in purple)}. Vertical lines
indicate doptRe for the corresponding tRe. d70, dRe and tRe maximizing g among the six subfigures
constitute the optimal treatment parameters. Here: d
opt∗∗
70 = 0.04, d
opt
Re = 0.012, t
opt
Re = 142.
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Figure 26. Tumor size along time using quantiles qα(ρi), α ∈ {5, 50, 95}, ρ ∈
{tTi , dTi , lprodAi , nM0i }. d70 = dmax, dT = q95(dTi), l
prod
A = q95(l
prod
Ai
). Top: tT = q5(tTi); Middle:
tT = q50(tTi); Bottom: tT = q95(tTi). For each subfigure, we observe from the slowest dynamic
(the lowest) to the fastest (the highest) the tumor size dynamic for nM0 = q5(nM0i ) in solid line
(black), nM0 = q50(nM0i ) in dashed line (red), nM0 = q95(nM0i ) in dotted line (green). The
vertical line (orange) at t = 70 indicates the beginning of treatment.
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Figure 27. T cell (solid line in green) and differentiated melanoma cell (dotted line in blue)
along time for different doses in ACT group. tT = q50(tTi), dT = q95(dTi), l
prod
A = q50(l
prod
Ai
),
nM0 = q50(nM0i ). Vertical line at t = 70 (in gray) indicates the beginning of therapy, the vertical
line at t ≥ 70 (in red) indicates the value of g(d70).
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